This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Safeguard Scientifics Announces Second Quarter 2013 Financial Results

Safeguard’s partner companies remain on track to achieve growth and operating, financial and strategic milestones. As a result, Safeguard reiterated aggregate partner company revenue guidance for 2013 to be between $250 million and $270 million. Results for Safeguard partner companies are reported on a one-quarter lag basis.

“We are encouraged by the steady growth of our partner companies and by the gradual improvement in both the domestic economy and deal flow climate,” said Stephen T. Zarrilli, President and CEO at Safeguard. “Although the M&A market remains a little spotty, by focusing on Safeguard’s core business in the near-term, we are confident that we can achieve strategic goals in the long-term. We maintain our intent to grow our stable of partner companies to 25 by year-end 2013, deploy capital with greater consistency, and achieve monetizations with aggregate cash-on-cash returns at a minimum of 2x cost. Through keen focus and consistent execution, we believe that we can drive Safeguard’s capital under management to a range of $550 million to $700 million by year-end 2015.”

“As of June 30, 2013, Safeguard had deployed $233 million of capital into its 20 current partner companies,” said Jeffrey B. McGroarty, Senior Vice President and Chief Financial Officer at Safeguard. “Our net cash, cash equivalents and marketable securities at the end of the quarter totaled $130.7 million, after subtracting the total carrying value of debt outstanding of $49.4 million. For the three months ended June 30, 2013, Safeguard’s net loss was $28.1 million, or $1.33 per share, compared to $10.1 million, or $0.48 per share, for the same period in 2012. For the six months ended June 30, 2013, Safeguard’s net loss was $40.1 million, or $1.90 per share, compared to $19.8 million, or $0.95 per share, for the same period in 2012.”

PARTNER COMPANY HIGHLIGHTS

 
KEY: Safeguard Partner Company Revenue Stages
Development Stage   Initial Revenue Stage   Expansion Stage   High Traction Stage

--

 

Pre-revenue

--

 

$0M to $5M in revenue

--

 

$5M to $20M in revenue

--

 

$20M+ in revenue

--

Proving out

--

Initial customers

--

Commercial grade solution

--

Significant

technology

--

Early market

--

Growing market

commercial traction

--

Developing prototype

penetration

penetration

--

Beta stage customers

--

Management team forming

--

Management team built out

--

Infrastructure being

--

Infrastructure in place

           

built

               

HEALTHCARE

AdvantEdge Healthcare Solutions, Inc. ( Warren, NJ — High Traction Stage)

AdvantEdge Healthcare Solutions (“AdvantEdge”) is a technology-enabled provider of healthcare revenue cycle and business management solutions that substantially improve decision-making, maximize financial performance, streamline operations and eliminate compliance risks for healthcare providers. AdvantEdge is recognized as one of the top 10 medical billing, coding and practice management companies in the U.S.; has more than 675 employees in eight regional offices in the U.S. and one office in Bangalore, India; and collects more than $1 billion annually for its physician, hospital, ambulatory surgery and large office-based clients. Safeguard has deployed $15.3 million in AdvantEdge since November 2006 and has a 40% primary ownership position.

1 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs